Technology News and Research

RSS

XRCC2 gene mutations cause increased breast cancer risk

Mutations in a gene called XRCC2 cause increased breast cancer risk, according to a study published today in the American Journal of Human Genetics. The study looked at families that have a history of the disease but do not have mutations in the currently known breast cancer susceptibility genes.

30 Mar 2012

BG Medical forms new digital services marketing division

BG Medical Technologies, Inc., a leader in medical marijuana professional services, announces the formation of a new digital services marketing division to create best-in-class asset management for cannabis related Internet properties.

30 Mar 2012

MO BIO introduces PowerMicrobiome RNA Isolation Kit

MO BIO Laboratories, Inc., the leader in soil, water and microbial nucleic acid purification, announces the launch of the PowerMicrobiome RNA Isolation Kit, the first kit available that is optimized for stool and gut material and provides high quality RNA for use in characterizing the human microbiome.

29 Mar 2012

Yogurt could be an excellent vehicle for delivery of heart-healthy n-3 fatty acids

Many consumers want to increase their intake of heart-healthy n-3 fatty acids, found naturally in fish and fish products, but find it difficult to consume the levels recommended by the American Heart Association.

29 Mar 2012

Evergreen utilizes spinal navigation system for Transforaminal Lumbar Interbody Fusion procedure

Evergreen Hospital, a statewide leader in minimally invasive spine surgery, today announced it had completed the first minimally invasive spinal surgery procedure in the region using a state-of-the-art spine navigation system.

29 Mar 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

CRT, EIF create £50M Cancer Research Technology Pioneer Fund

Cancer Research Technology, (CRT) Cancer Research UK's commercial arm, and the European Investment Fund (EIF) have joined together to create a £50M investment fund to bridge the funding gap in the UK between cancer drug discovery and early development.

29 Mar 2012

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced results from its recently completed Phase 1 clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure.

29 Mar 2012

One-side parathyroid surgery has poorer long-term outcomes

Dr James Norman, MD and his partners at the Norman Parathyroid Center have published a landmark study in this week's Journal of the American College of Surgeons describing how the operation they developed and advocated for more than 19 years has significantly poorer long-term outcomes. The unilateral or "one-side" parathyroid surgical procedure to remove parathyroid tumors from patients suffering from hyperparathyroidism is a dramatic change from the large neck operation that it replaced.

29 Mar 2012

Daiichi Sankyo, NGM to discover and develop new treatments for diabetes

Daiichi Sankyo Company, Ltd. and NGM Biopharmaceuticals, Inc. announced today that they have entered into a research collaboration and license agreement to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

29 Mar 2012

UTHealth, PLx Pharma to test phosphatidylcholine-enriched version of indomethacin in PDA model

PLx Pharma Inc, a Houston-based pharmaceutical company developing a medical discovery made at The University of Texas Health Science Center at Houston (UTHealth) Medical School, has been awarded $565,449 for the first year of a potential two-year $1,118,398 grant to conduct research designed to enhance a treatment for premature babies with a common congenital heart defect.

29 Mar 2012

VasoStitch percutaneous access-and-closure system featured at ACC annual meeting

VasoStitch is developing a percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an "open" surgical procedure.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

DUHS chooses M*Modal's Speech Understanding technology

M*Modal, a leading provider of clinical documentation services and Speech Understanding technologies, today announced that Duke University Health System (DUHS) has selected the Company's cloud-based Speech Understanding technology to support the rollout of its Epic electronic health record.

29 Mar 2012

Bristol-Myers Squibb, Meso Scale Discovery collaborate to advance AD research

Bristol-Myers Squibb Company and Meso Scale Discovery today announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

29 Mar 2012

Top-five pharma manufacturer implements ALSCG MemberMATCH GPO solution

Alliance Life Sciences Consulting Group, a leading management and technology consultancy, announces the implementation of MemberMATCH at a top-five pharmaceutical manufacturer.

29 Mar 2012

Affymetrix' GeneChip technology incorporated into Lineagen's FirstStepDx genetic evaluation service

Affymetrix, Inc. and Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, today announced the companies have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's next-generation FirstStepDx, a genetic evaluation service for individuals with developmental delay (DD), intellectual disability (ID), and autism spectrum disorders (ASD).

29 Mar 2012

AFB announces Access Award recipients for 2012

What do the leaders of "America's pastime," a free open-source screen-reading software company, an orientation and mobility (O&M) program, and the founder of Camp Abilities have in common? All have taken successful strides toward creating a better quality of life for people who are blind or visually impaired, which is why they were named the recipients of the 2012 Access Awards, announced today by the American Foundation for the Blind.

29 Mar 2012